Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights
PHILADELPHIA, March 06, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided recent business highlights.
Related news for (PASG)
- Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights